The Ca2+ -antagonist and Binding Properties of the Phenylalkylamine, Anipamil

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 1988 May 1

PMID 2456811

Citations 4

Authors

J S Dillon

W G NAYLER

Affiliations

Soon will be listed here.

Abstract

1. Isolated, Langendorff-perfused rat hearts, isolated membranes, and pharmacological and receptor binding techniques were used to study the properties of the newly developed verapamil derivative, anipamil. 2. When added acutely to isolated, spontaneously beating or electrically paced hearts, anipamil (0.01-0.15 microM) exerted a dose-dependent negative inotropic effect which developed slowly and persisted after 60 min washout. 3. When added acutely (0.05-0.1 microM) to isolated hearts, or when given intravenously (2 mg kg-1 body weight 1 h before the animals were killed), anipamil displaced the dose-response curves for the positive inotropic effect of (0.10-3.0 mM) Ca2+ and (10-50 nM) Bay K 8644 to the right. 4. When added to freshly isolated cardiac membranes, 0.1 microM anipamil increased the dissociation constant (KD) of the phenylalkylamine (-)-[3H]-desmethoxyverapamil ((-)-[3H]-D888) from 1.22 +/- 0.2 to 2.91 +/- 0.46 nM, without any significant change in density (Bmax; control: 163 +/- 17; anipamil: 117 +/- 20 fmol mg-1 protein). Bound (-)-[3H]-D888 was displaceable by (-)-D888 (Ki 1.7 +/- 0.4 nM) greater than (-)-D600 (Ki 12 +/- 0.5 nM) greater than verapamil (Ki 55 +/- 11 nM) greater than (+)-D600 (Ki 108 +/- 12.2) greater than anipamil (Ki 471 +/- 52 nM). 5. In cardiac membranes isolated from rats pretreated with anipamil (2 mg kg-1 i.v.) 1h before they were killed, the KD of (-)-[3H]-D888 binding was increased (P less than 0.05) from 1.59 +/- 0.18 to 3.28 +/-0.65 nM with no significant change in density, compared to the placebo-treated (control) rats. 6. These results establish that anipamil interacts in a competitive manner with the phenylalkylamine binding sites in cardiac membranes, and that it resembles other Ca2+ antagonists in displacing the dose-response curve for the positive inotropic effect of Ca2+ to the right. The results also show that although anipamil binds tightly to the cardiac membranes, it binds to the (-)-[3H]-D888 recognition sites less potently than (-)-D888, (-)-D600 or verapamil.

Citing Articles

Anipamil prevents ST depression in patients with stable angina pectoris.

Larsen C, Sorum C, Rasmussen V, Hansen J Cardiovasc Drugs Ther. 1993; 7(6):915-21.

PMID: 8011571 DOI: 10.1007/BF00877727.

Effects of anipamil on cardiovascular status and regional blood flow in anaesthetized rats.

Tabrizchi R, Pang C, Walker M Br J Pharmacol. 1989; 98(4):1185-90.

PMID: 2611488 PMC: 1854806. DOI: 10.1111/j.1476-5381.1989.tb12663.x.

The antiarrhythmic efficacy of intravenous anipamil against occlusion and reperfusion arrhythmias.

MacLeod B, Moult M, Saint K, Walker M Br J Pharmacol. 1989; 98(4):1165-72.

PMID: 2611487 PMC: 1854811. DOI: 10.1111/j.1476-5381.1989.tb12661.x.

Effects of the novel calcium channel blocker, anipamil, on the isolated rabbit heart. Comparison with verapamil and gallopamil.

Raddino R, Poli E, Pasini E, Ferrari R Naunyn Schmiedebergs Arch Pharmacol. 1992; 346(3):339-44.

PMID: 1383837 DOI: 10.1007/BF00173549.

References

NAYLER W, McInnes I, Swann J, Price J, Carson V, Race D . Some effects of iproveratril (Isoptin) on the cardiovascular system. J Pharmacol Exp Ther. 1968; 161(2):247-61. View

LOWRY O, ROSEBROUGH N, FARR A, RANDALL R . Protein measurement with the Folin phenol reagent. J Biol Chem. 1951; 193(1):265-75. View

NAYLER W, Szeto J . Effect of verapamil on contractility, oxygen utilization, and calcium exchangeability in mammalian heart muscle. Cardiovasc Res. 1972; 6(2):120-8. DOI: 10.1093/cvr/6.2.120. View

Smith H, Goldstein R, Griffith J, Kent K, Epstein S . Regional contractility. Selective depression of ischemic myocardium by verapamil. Circulation. 1976; 54(4):629-35. DOI: 10.1161/01.cir.54.4.629. View

Munson P, Rodbard D . Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem. 1980; 107(1):220-39. DOI: 10.1016/0003-2697(80)90515-1. View

NAYLER W, Scott E . The effect of chemical sympathectomy on mitochondrial function in the ischaemic and reperfused myocardium. Br J Pharmacol. 1982; 77(4):707-15. PMC: 2044678. DOI: 10.1111/j.1476-5381.1982.tb09350.x. View

Schramm M, Thomas G, Towart R, Franckowiak G . Novel dihydropyridines with positive inotropic action through activation of Ca2+ channels. Nature. 1983; 303(5917):535-7. DOI: 10.1038/303535a0. View

McPherson G . A practical computer-based approach to the analysis of radioligand binding experiments. Comput Programs Biomed. 1983; 17(1-2):107-13. DOI: 10.1016/0010-468x(83)90031-4. View

Kokubun S, Reuter H . Dihydropyridine derivatives prolong the open state of Ca channels in cultured cardiac cells. Proc Natl Acad Sci U S A. 1984; 81(15):4824-7. PMC: 391583. DOI: 10.1073/pnas.81.15.4824. View

10.

Goll A, Ferry D, Striessnig J, Schober M, Glossmann H . (-)-[3H]Desmethoxyverapamil, a novel Ca2+ channel probe. Binding characteristics and target size analysis of its receptor in skeletal muscle. FEBS Lett. 1984; 176(2):371-7. DOI: 10.1016/0014-5793(84)81199-0. View

11.

Ferry D, Goll A, Gadow C, Glossmann H . (-)-3H-desmethoxyverapamil labelling of putative calcium channels in brain: autoradiographic distribution and allosteric coupling to 1,4-dihydropyridine and diltiazem binding sites. Naunyn Schmiedebergs Arch Pharmacol. 1984; 327(2):183-7. DOI: 10.1007/BF00500915. View

12.

Glossmann H, Ferry D . Assay for calcium channels. Methods Enzymol. 1985; 109:513-50. DOI: 10.1016/0076-6879(85)09112-1. View

13.

Ruth P, Flockerzi V, von Nettelbladt E, Oeken J, Hofmann F . Characterization of the binding sites for nimodipine and (-)-desmethoxyverapamil in bovine cardiac sarcolemma. Eur J Biochem. 1985; 150(2):313-22. DOI: 10.1111/j.1432-1033.1985.tb09023.x. View

14.

Osborne J, Darius H, Lefer A . In vivo anti-platelet properties of anipamil, a calcium channel blocker, in the rabbit. Res Commun Chem Pathol Pharmacol. 1986; 52(2):167-78. View

15.

Curtis M, Walker M, Yuswack T . Actions of the verapamil analogues, anipamil and ronipamil, against ischaemia-induced arrhythmias in conscious rats. Br J Pharmacol. 1986; 88(2):355-61. PMC: 1916825. DOI: 10.1111/j.1476-5381.1986.tb10211.x. View

16.

Posner P, Baker S, Isaacson R . Potentiation of the negative chronotropic action of verapamil by ethanol. J Cardiovasc Pharmacol. 1986; 8(4):697-9. View

17.

Dillon J, NAYLER W . [3H]-verapamil binding to rat cardiac sarcolemmal membrane fragments; an effect of ischaemia. Br J Pharmacol. 1987; 90(1):99-109. PMC: 1917274. DOI: 10.1111/j.1476-5381.1987.tb16829.x. View

18.

VATER W, KRONEBERG G, HOFFMEISTER F, Saller H, Meng K, OBERDORF A . [Pharmacology of 4-(2'-nitrophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid dimethyl ester (Nifedipine, BAY a 1040)]. Arzneimittelforschung. 1972; 22(1):1-14. View